| CAS NO: | 1129433-63-1 |
| 包装 | 价格(元) |
| 500 μg | 电议 |
| 1mg | 电议 |
| Cas No. | 1129433-63-1 |
| 别名 | 考尼伐坦杂质 |
| Canonical SMILES | O=C(NC1=C([2H])C([2H])=C(C(N2CCC(N=C(C)N3)=C3C4=C2C=CC=C4)=O)C([2H])=C1[2H])C(C=CC=C5)=C5C6=CC=CC=C6 |
| 分子式 | C32H22D4N4O2 |
| 分子量 | 502.6 |
| 溶解度 | DMSO: soluble |
| 储存条件 | Store at -20°C |
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while. |
| Shipping Condition | Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request |
| 产品描述 | Conivaptan-d4is intended for use as an internal standard for the quantification of conivaptan by GC- or LC-MS. Conivaptan is an antagonist of the arginine vasopressin (AVP) receptors V1Aand V2(Kis = 0.48 and 3.04 nM for rat liver V1Aand kidney V2, respectively).1It also competitively inhibits oxytocin binding to rat uterine oxytocin receptors (Ki= 44 nM) but has no effect on AVP binding to anterior pituitary V1Breceptors at concentrations up to 100 μM in a radioligand binding assay. Conivaptan suppresses AVP-induced increases in intracellular calcium in vascular smooth muscle cells (VSMCs)in vitroand the pressor response in pithed rats. Conivaptan (0.01-0.3 mg/kg, i.v.) increases urine output and decreases urine osmolality in dehydrated conscious rats in a dose-dependent manner. It also reduces brain edema and blood-brain barrier disruption in a mouse experimental stroke model.2 1.Tahara, A., Tomura, Y., Wada, K.-I., et al.Pharmacological profile of YM087, a novel potent nonpeptide vasopressin V1A and V2 receptor antagonist, in vitro and in vivoJ. Pharmacol. Exp. Ther.282(1)301-308(1997) 2.Zeynalov, E., Jones, S.M., Seo, J.W., et al.Arginine-vasopressin receptor blocker conivaptan reduces brain edema and blood-brain barrier disruption after experimental stroke in micePLoS One10(8)e0136121(2015) |
m.cnreagent.com